Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2023 16:15 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) --...
July 12, 2023 08:00 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company...
November 30, 2022 07:00 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients

Los Gatos, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
November 21, 2022 18:30 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update

Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aridis...